Listening for prescriptions: A national consultation on pharmaceutical policy issues

Healthcare Policy

Volumn 6, Issue 2, 2010, Pages 48-66

  Morgan, Steve ^a   Cunningham, Colleen M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANADA; CONSENSUS; CONSULTATION; FINANCIAL MANAGEMENT; FRUSTRATION; HEALTH CARE; HUMAN; MEDICINE; MOTIVATION; POLICY; PRESCRIPTION; PUBLICATION; RESEARCH PRIORITY; WORKSHOP;

EID: 79851475385     PISSN: None     EISSN: 17156572     Source Type: Journal    
DOI: 10.12927/hcpol.2010.22034     Document Type: Article

References (47)

1. Avorn, J. 2004. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York: Knopf.
2. Bell, R.A., R.L. Kravitz and M.S. Wilkes. 2000. "Direct-to-Consumer Prescription Drug Advertising, 1989-1998. A Content Analysis of Conditions, Targets, Inducements, and Appeals." Journal of Family Practice 49(4): 329-35. (Pubitemid 30489247)
3. Boothe, K. 2010. Pharmaceutical Programs and Social Policy Development: Comparing Canada, Australia and the UK (p. 158). PhD thesis, Political Science, University of British Colombia. Retrieved October 8, 2010. 〈https://circle. ubc.ca/bitstream/handle/2429/26266/ubc-2010-fall-boothe-katherine.pdf?sequence= 3〉.
4. Cadieux, G.M., R.P. Tamblyn, D.M.D. Dauphinee and M.M.D. Libman. 2007. "Predictors of Inappropriate Antibiotic Prescribing among Primary Care Physicians." Canadian Medical Association Journal 177(8): 877-83.
5. Canada. 1963. Report Concerning the Manufacture, Distribution and Sale of Drugs. Ottawa: Department of Justice, Restrictive Trade Practices Commission.
6. Canada. 1965. Provision, Distribution and Cost of Drugs in Canada. Royal Commission on Health Services. Ottawa: Queen's Printer.
7. Canada. 1985. Report of the Commission of Inquiry on the Pharmaceutical Industry. Ottawa: Supply and Services Canada.
8. Canada. 1998. "Directions for a Pharmaceutical Policy in Canada." Canada Health Action: Building on the Legacy. Synthesis Reports and Issues Papers Volume II. Ottawa: National Forum on Health.
9. Canada. 2002. "Chapter 9: Prescription Drugs." Building on Values: The Future of Health Care in Canada - Final Report. Saskatoon: Commission on the Future of Health Care in Canada. Retrieved October 8, 2010. 〈http://dsp-psd.pwgsc.gc.ca/Collection/CP32-85-2002E.pdf〉.
10. Canada. 2004. "First Minister's Meeting on the Future of Health Care 2004: A 10-Year Plan to Strengthen Health Care." Retrieved October 8, 2010. 〈http://www.hc-sc.gc.ca/hcs-sss/delivery-prestation/fptcollab/2004- fmm-rpm/index-e.html〉.
11. Canadian Agency for Drugs and Technologies in Health (CADTH). 2010. The Rx for Change Database. Retrieved October 8, 2010. 〈http://www.cadth.ca/ index.php/en/compus/optimal-therresources/interventions〉.
12. Canadian Health Services Research Foundation (CHSRF). 2001. Listening for Direction: A National Consultation on Health Services and Policy Issues. Ottawa: Canadian Health Services Research Foundation.
13. Canadian Institute for Health Information (CIHI). 2010. Drug Expenditure in Canada, 1985-2009. Retrieved October 8, 2010. 〈http://secure.cihi.ca/ cihiweb/products/dex-1985-to-2009-e.pdf〉.
14. Competition Bureau. 2007. Generic Drug Sector Study (p. 66). Ottawa: Competition Bureau Canada.
15. Dault, M., J. Lomas and M. Barer (on behalf of the Listening for Direction II Partners). 2004. Listening for Direction II. Retrieved October 8, 2010. 〈http://www.chsrf.ca/other-documents/listening/index2-e.php〉.
16. Deyo, R.A. 2004. "Gaps, Tensions, and Conflicts in the FD A Approval Process: Implications for Clinical Practice." Journal of the American Board of Family Practice 17(2): 142-49.
17. Evans, R.G., C. Hertzman and S. Morgan. 2007. "Improving Health Outcomes in Canada." In J. Leonard, C. Ragan, F. St-Hilaire, eds., A Canadian Priorities Agenda: Policy Choices to Improve Economic and Social Well-Being (pp. 291-325). Montreal: Institute for Research on Public Policy.
18. Evans, R.G. and M.F. Williamson. 1978. Extending Canadian Health Insurance: Options for Pharmacare and Denticare. Toronto: Published for the Ontario Economic Council by University of Toronto Press.
19. Frosch, D.L., P.M. Krueger, R.C. Hornik, P.F. Cronholm and F.K. Barg. 2007. "Creating Demand for Prescription Drugs: A Content Analysis of Television Direct-to-Consumer Advertising." Annals of Family Medicine 5: 6-13. (Pubitemid 46193203)
20. Gahart, M.T., L.M. Duhamel, A. Dievler and R. Price. 2003. "Examining the FDA's Oversight of Direct-to-Consumer Advertising." Health Affairs (Millwood): W3-120.
21. Health Council of Canada. 2009. A Status Report on the National Pharmaceuticals Strategy: A Prescription Unfilled. Toronto: Health Council.
22. Hollis, A. 2002. "The Importance of Being First: Evidence from Canadian Generic Pharmaceuticals." Health Economics 11(8): 723-34. (Pubitemid 36013521)
23. Hollis, A. 2005. "Drugs for Rare Diseases: Paying for Innovation." In C. Beach, R. Chaykowski, S. Shortt, F. St-Hilaire and A. Sweetman, eds., Health Services Restructuring in Canada: New Evidence and New Directions. Kingston: McGill-Queens University Press.
24. Hutchinson, J.M. and R.N. Foley. 1999. "Method of Physician Remuneration and Rates of Antibiotic Prescription." Canadian Medical Association Journal 160(7): 1013-17. (Pubitemid 29176745)
25. IMS Health Incorporated. 2010 (April 23). "IMS Forecasts Global Pharmaceutical Market Growth of 5-8% Annually through 2014; Maintains Expectations of 4-6% Growth in 2010." Retrieved October 8, 2010. 〈http://www.europeanpharmaceuticalreview.com/news/industry-news/ ims-forecasts-global-pharmaceutical-market-growth-of-5-8-annually-through-2014- maintains-expectations-of-4-6-growth-in-2010/〉.
26. Kaphingst, K.A., W. DeJong, R.E. Rudd and L.H. Daltroy. 2004. "A Content Analysis of Direct-to-Consumer Television Prescription Drug Advertisements." Journal of Health Communication 9(6): 515-28. (Pubitemid 40115880)
27. Kennedy, J. and S. Morgan. 2009. "Cost-Related Prescription Nonadherence in the United States and Canada: A System-Level Comparison Using the 2007 International Health Policy Survey in Seven Countries." Clinical Therapeutics 31(1): 213-19.
28. Law, S., C. Flood and D. Gagnon (on behalf of the Listening for Direction III Partners). 2008. Listening for Direction III. Final Report. Retrieved October 8, 2010. 〈http://www.chsrf.ca/other-documents/listening/index-e. php〉.
29. Lexchin, J. 1993. "Pharmaceuticals, Patents, and Politics: Canada and Bill C-22." International Journal of Health Services 23(1): 147-60. (Pubitemid 23050381)
30. Lippman, A. 2006 (March). "The Inclusion of Women in Clinical Trials: Are We Asking the Right Questions?" Toronto: Women and Health Protection. Retrieved October 8, 2010. 〈http://www.whp-apsf.ca/pdf/ clinicalTrialsEN.pdf〉.
31. Lomas, J., N. Fulop, D. Gagnon and P. Allen. 2003. "On Being a Good Listener: Setting Priorities for Applied Health Services Research." Milbank Quarterly 81(3): 363-88. (Pubitemid 37346996)
32. MacKinnon, N.J. and Canadian Pharmacists Association. 2007. Safe and Effective: The Eight Essential Elements of an Optimal Medication-Use System. Ottawa: Canadian Pharmacists Association.
33. Maynard, A. 1999. "Rationing Health Care: An Exploration." Health Policy 49(1-2): 5-11. (Pubitemid 29516466)
34. McCabe, C., K. Claxton and A. Tsuchiya. 2005. "Orphan Drugs and the NHS: Should We Value Rarity?" British Medical Journal 331(7523): 1016-19. (Pubitemid 41552456)
35. Menon, D., T. Stafinski and G. Stuart. 2005. "Access to Drugs for Cancer - Does Where You Live Matter?" Canadian Journal of Public Health 96(6): 454-58. (Pubitemid 41762922)
36. Milewa, T. 2008. "Representation and Legitimacy in Health Policy Formulation at a National Level: Perspectives from a Study of Health Technology Eligibility Procedures in the United Kingdom." Health Policy 85(3): 356-62. (Pubitemid 351179538)
37. Mitton, C.R., M. McMahon, S. Morgan and J. Gibson. 2006. "Centralized Drug Review Processes: Are They Fair?" Social Science and Medicine 63(1): 200-11. (Pubitemid 43668407)
38. Morgan, S., G. Hanley, C. Raymond and R. Blais. 2009. "Breadth, Depth and Agreement among Provincial Formularies in Canada." Healthcare Policy 4(4): e162-e184.
39. Morgan, S., J. Kennedy, K. Boothe, M. McMahon, D. Watson and E. Roughead. 2009. "Toward an Understanding of High Performance Pharmaceutical Policy Systems: A 'Triple-A' Framework and Example Analysis." Open Health Services and Policy Journal 2(1): 1-9.
40. Sansom, L. 1999. "The Australian National Medicinal Drug Policy." Journal of Quality in Clinical Practice 19(1): 31-35. (Pubitemid 29111576)
41. Schoen, C., R. Osborn, M.M. Doty, D. Squires, J. Peugh and S. Applebaum. 2009. "A Survey of Primary Care Physicians in Eleven Countries, 2009: Perspectives on Care, Costs, and Experiences." Health Affairs (Millwood) 28(6): w1171-83.
42. Sherr, L. 2000. "Women and Clinical Trials." In L. Sherr and J.S. St. Lawrence, Women, Health and the Mind (pp. 47-58). Chichester, UK: Wiley.
43. Syrett, K. 2003. "A Technocratic Fix to the 'Legitimacy Problem'? The Blair Government and Health Care Rationing in the United Kingdom." Journal of Health Politics Policy and Law 28(4): 715-46. (Pubitemid 37012995)
44. Tamblyn, R., P. McLeod, J.A. Hanley, N. Girard and J. Hurley. 2003. "Physician and Practice Characteristics Associated with the Early Utilization of New Prescription Drugs." Medical Care 41(8): 895-908.
45. Taylor, M.G. 2009. Health Insurance and Canadian Public Policy: The Seven Decisions that Created the Canadian Health Insurance System and Their Outcomes. Montreal: McGill-Queen's University Press.
46. Temin, P. 1980. Taking Your Medicine: Drug Regulation in the United States. Cambridge, MA: Harvard University Press.
47. World Health Organization (WHO). 2001. How to Develop and Implement a National Drug Policy (2nd ed.). Geneva: World Health Organization.